+23.0%
ASML vs MRNA
+171.6%
-148.7%
-22.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.2% | -2.2% | +6.4% | +4.2% |
| 7D | +1.1% | +5.5% | -4.4% | +1.1% |
| 30D | +2.2% | +158.7% | -156.5% | -0.4% |
| 3M | -2.3% | +182.1% | -184.4% | -12.3% |
| 6M | +23.0% | +151.8% | -128.8% | +15.5% |
| All | +23.0% | +171.6% | -148.7% | +15.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling